Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Richard S. Hoehn

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1455-6758; OpenAlex author ID A5041574571. Sources: OpenAlex.

Their work

Papers
11 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 5 papers · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers

Papers 11

  1. Understanding surgical attrition for "resectable" pancreatic cancer. Last author DOI 10.1016/j.hpb.2023.11.008↗
  2. Pancreatic Cancer Multidisciplinary Clinic is Associated with Improved Treatment and Elimination of Socioeconomic Disparities. Co-author DOI 10.1245/s10434-023-14609-7↗
  3. Disparities in guideline-compliant care for patients with pancreatic ductal adenocarcinoma at minority-versus non-minority-serving hospitals. First author DOI 10.1016/j.hpb.2023.07.903↗
  4. Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenocarcinoma. Co-author DOI 10.1016/j.hpb.2022.07.007↗
  5. Medicaid expansion and the management of pancreatic cancer. Co-author DOI 10.1002/jso.26515↗
  6. Safety and oncologic efficacy of robotic compared to open pancreaticoduodenectomy after neoadjuvant chemotherapy for pancreatic cancer. Co-author DOI 10.1007/s00464-020-07638-w↗
  7. Impact of Resection Margin Status in Patients with Pancreatic Cancer: a National Cohort Study. Co-author DOI 10.1007/s11605-020-04870-6↗
  8. Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma Lessens the Deleterious Effect of Omission of Adjuvant Chemotherapy. Co-author DOI 10.1245/s10434-020-09446-x↗
  9. A Pancreatic Cancer Multidisciplinary Clinic Eliminates Socioeconomic Disparities in Treatment and Improves Survival. Co-author DOI 10.1245/s10434-021-09594-8↗
  10. Long-term oncologic outcomes of robotic and open pancreatectomy in a national cohort of pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.25958↗
  11. Equivalent Treatment and Survival after Resection of Pancreatic Cancer at Safety-Net Hospitals. First author DOI 10.1007/s11605-017-3549-0↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Amer H. Zureikat · 7 shared papers, 2020–2024 · strength 1.00
  2. Alessandro Paniccia · 7 shared papers, 2020–2024 · strength 1.00
  3. Ibrahim Nassour · 5 shared papers, 2020–2021 · strength 0.67
  4. Samer T. Tohme · 4 shared papers, 2020–2021 · strength 0.53
  5. Mohamedraed Elshami · 3 shared papers, 2022–2024 · strength 0.53
  6. John Brian Ammori · 3 shared papers, 2022–2024 · strength 0.53
  7. Lee Mayer Ocuin · 3 shared papers, 2022–2024 · strength 0.53
  8. Jeffrey M. Hardacre · 3 shared papers, 2022–2024 · strength 0.53
  9. Jordan Michael Winter · 3 shared papers, 2022–2024 · strength 0.53
  10. Caroline J. Rieser · 3 shared papers, 2021–2024 · strength 0.46
  11. Mohamed A. Adam · 3 shared papers, 2020–2021 · strength 0.41
  12. Hanna H. Kakish · 2 shared papers, 2022–2024 · strength 0.35
  13. David L. Bartlett · 3 shared papers, 2020–2021 · strength 0.34
  14. David Lawrence Bajor · 2 shared papers, 2022–2023 · strength 0.31
  15. Christof Kaltenmeier · 2 shared papers, 2021 · strength 0.26
  16. Nathan Bahary · 2 shared papers, 2021 · strength 0.23
  17. Sakti Chakrabarti · 1 shared paper, 2023 · strength 0.17
  18. Amit Mahipal · 1 shared paper, 2023 · strength 0.17
  19. Luke Daniel Rothermel · 1 shared paper, 2022 · strength 0.14
  20. Jonathan J. Hue · 1 shared paper, 2022 · strength 0.14
  21. Callie A. Hlavin · 1 shared paper, 2021 · strength 0.13
  22. Rohit Kumar Das · 1 shared paper, 2021 · strength 0.09
  23. Melissa Ellen Hogg · 1 shared paper, 2021 · strength 0.09
  24. Susannah G. Ellsworth · 1 shared paper, 2021 · strength 0.09
  25. Adam C. Olson · 1 shared paper, 2021 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.